Targeting G Protein-Coupled Receptors by Capture Compound Mass Spectrometry: A Case Study with Sertindole.

Autor: Blex, Christian, Michaelis, Simon, Schrey, Anna K., Furkert, Jens, Eichhorst, Jenny, Bartho, Kathrin, Gyapon Quast, Frederick, Marais, Anett, Hakelberg, Matthias, Gruber, Uschi, Niquet, Sylvia, Popp, Oliver, Kroll, Friedrich, Sefkow, Michael, Schülein, Ralf, Dreger, Mathias, Köster, Hubert

Publikováno v: ChemBioChem; Aug2017, Vol. 18 Issue 16, p1639-1649, 11p

Semisynthetic Glycoconjugate Vaccine Candidates against Escherichia coliO25B Induce Functional IgG Antibodies in Mice

Autor: Naini, Arun, Bartetzko, Max Peter, Sanapala, Someswara Rao, Broecker, Felix, Wirtz, Victoria, Lisboa, Marilda P., Parameswarappa, Sharavathi G., Knopp, Daniel, Przygodda, Jessica, Hakelberg, Matthias, Pan, Rosalind, Patel, Axay, Chorro, Laurent, Illenberger, Arthur, Ponce, Christopher, Kodali, Srinivas, Lypowy, Jacqueline, Anderson, Annaliesa S., Donald, Robert G. K., von Bonin, Arne, Pereira, Claney L.

Publikováno v: JACS Au; 20220101, Issue: Preprints

Semisynthetic Glycoconjugate Vaccine Candidates against Escherichia coli O25B Induce Functional IgG Antibodies in Mice.

Autor: Naini A; Vaxxilon Deutschland GmbH, Part of Idorsia Pharmaceuticals Ltd., Magnusstr. 11, 12489 Berlin, Germany., Bartetzko MP; Vaxxilon Deutschland GmbH, Part of Idorsia Pharmaceuticals Ltd., Magnusstr. 11, 12489 Berlin, Germany., Sanapala SR; Vaxxilon Deutschland GmbH, Part of Idorsia Pharmaceuticals Ltd., Magnusstr. 11, 12489 Berlin, Germany., Broecker F; Vaxxilon Deutschland GmbH, Part of Idorsia Pharmaceuticals Ltd., Magnusstr. 11, 12489 Berlin, Germany., Wirtz V; Vaxxilon Deutschland GmbH, Part of Idorsia Pharmaceuticals Ltd., Magnusstr. 11, 12489 Berlin, Germany., Lisboa MP; Vaxxilon Deutschland GmbH, Part of Idorsia Pharmaceuticals Ltd., Magnusstr. 11, 12489 Berlin, Germany., Parameswarappa SG; Vaxxilon Deutschland GmbH, Part of Idorsia Pharmaceuticals Ltd., Magnusstr. 11, 12489 Berlin, Germany., Knopp D; Vaxxilon Deutschland GmbH, Part of Idorsia Pharmaceuticals Ltd., Magnusstr. 11, 12489 Berlin, Germany., Przygodda J; Vaxxilon Deutschland GmbH, Part of Idorsia Pharmaceuticals Ltd., Magnusstr. 11, 12489 Berlin, Germany., Hakelberg M; Vaxxilon Deutschland GmbH, Part of Idorsia Pharmaceuticals Ltd., Magnusstr. 11, 12489 Berlin, Germany., Pan R; Pfizer Vaccine Research and Development, Pearl River, New York 10965, United States., Patel A; Pfizer Vaccine Research and Development, Pearl River, New York 10965, United States., Chorro L; Pfizer Vaccine Research and Development, Pearl River, New York 10965, United States., Illenberger A; Pfizer Vaccine Research and Development, Pearl River, New York 10965, United States., Ponce C; Pfizer Vaccine Research and Development, Pearl River, New York 10965, United States., Kodali S; Pfizer Vaccine Research and Development, Pearl River, New York 10965, United States., Lypowy J; Pfizer Vaccine Research and Development, Pearl River, New York 10965, United States., Anderson AS; Pfizer Vaccine Research and Development, Pearl River, New York 10965, United States., Donald RGK; Pfizer Vaccine Research and Development, Pearl River, New York 10965, United States., von Bonin A; Vaxxilon Deutschland GmbH, Part of Idorsia Pharmaceuticals Ltd., Magnusstr. 11, 12489 Berlin, Germany., Pereira CL; Vaxxilon Deutschland GmbH, Part of Idorsia Pharmaceuticals Ltd., Magnusstr. 11, 12489 Berlin, Germany.

Publikováno v: JACS Au [JACS Au] 2022 Aug 31; Vol. 2 (9), pp. 2135-2151. Date of Electronic Publication: 2022 Aug 31 (Print Publication: 2022).